The Novartis 4 Bold Approaches to Cancer TreatmentLearn More
This material is intended for non-US healthcare professionals only.
Please note that access is not permitted in the case that the US is your primary country of residence.
This microsite includes resources that were developed in accordance to the EU label for LUTATHERA: Indication for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. LUTATHERA is registered in the European Economic Area, United States, Canada, Israel, Switzerland, Hong Kong, Singapore and South Korea. Registration conditions may differ from country to country. Please refer to your locally approved license and prescribing information